ArticleScientific reports2026
Extensive screening of ten bacteriophage cocktails revealed an optimal combination with potent therapeutic activity against Acinetobacter baumannii.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in phage therapy forFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) Acinetobacter baumannii poses a major clinical challenge due to its association with high morbidity and mortality, necessitating alternative treatment strategies. Bacteriophages offer a promising solution; however, their narrow host range limits efficacy against diverse A. baumannii strains. To address this limitation, we isolated five distinct phages (vB_AbaSI_1–5) of the class Caudoviricetes, each exhibiting a narrow host range (2.2%-29.6%) against 135 clinical A. baumannii isolates. Ten phage cocktails (A-J) were formulated and tested for host range expansion and bactericidal activity. Cocktails A, D, and E demonstrated enhanced efficacy, infecting 68 of 135 isolates (50.4%) and statistically significantly outperforming individual phages (p < 0.0001). Among these, cocktail A (comprising phages vB_AbaSI_1, vB_AbaSI_2, and vB_AbaSI_3) exhibited the highest killing efficiency against extensively drug-resistant A. baumannii strain DMST43250, along with superior biofilm inhibition and degradation capabilities. Application of cocktail A completely inhibited biofilm formation within 24 h. In vivo efficacy was evaluated using a Galleria mellonella infection model, in which cocktail A improved larval survival to 85.0% on day 1 and 60.0% by day 7, exceeding other cocktails (p < 0.0001). These results highlight cocktail A as a promising candidate for phage therapy targeting A. baumannii infections and associated biofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.